FDA Adverse Event Injury Summary report: N

ICL (IMPLANTABLE COLLAMER LENS)

MDR report key: 2141116 · Received June 22, 2011

Report

Report Number
2023826-2011-00554
Event Type
Injury
Date Received
June 22, 2011
Date of Event
May 26, 2011
Report Date
May 27, 2011
Manufacturer
STAAR SURGICAL CO.
Product Code
MTA
PMA / PMN Number
P030016
Removal / Correction Number
NA
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Occupation
PHYSICIAN

Narratives

Additional Manufacturer Narrative · 1

(B)(4). CONCLUSION: AT THE CONCLUSION OF THE ORIGINAL INVESTIGATION OPENED FOR THE ISSUE OF ICL VAULTING (BOTH INADEQUATE AND EXCESSIVE), IT WAS DETERMINED THAT THE MOST LIKELY ROOT CAUSE FOR BOTH INADEQUATE AND EXCESSIVE VAULT IS DIFFICULTY IN CLINICAL SIZING. IN NO CASE HAS A RETURNED LENS EXHIBITED A LENGTH MEASUREMENT OUTSIDE THE EXPECTED RANGE ACCORDING TO THE LABELED LENGTH. PRE-OPERATIVE MEASUREMENT TECHNOLOGY AVAILABLE TO CLINICIANS IN THE PAST DID NOT PROVIDE A DIRECT MEASUREMENT OF THE SULCUS, TO WHICH THE ICL SHOULD BE SIZED. THE CURRENT PRACTICE IN SELECTING AN APPROPRIATE ICL FOR A PATIENT IS TO MEASURE WHITE-TO-WHITE AND ANTERIOR CHAMBER DEPTH AND, THROUGH CORRELATIVE ALGORITHMS, PREDICT THE LENGTH OF THE ICL THAT WILL BRIDGE THE SULCUS. THIS METHOD OF SIZING BASED UPON WHITE-TO-WHITE AND ANTERIOR CHAMBER DEPTH MEASUREMENTS WAS USED IN THE FDA CLINICAL TRIAL AND IS RECOMMENDED IN THE CURRENT LABELING OF THE ICL. IF THE PREDICTED LENGTH IS TOO SHORT, THE RESULT MAY BE AN INADEQUATE VAULT. IF THE PREDICTED LENGTH IS TOO LONG, THE RESULT MAY BE AN EXCESSIVE VAULT. (B)(4).

Description of Event or Problem · 1

IT WAS REPORTED THAT THE SURGEON INSERTED A VICM13.7 IMPLANTABLE COLLAMER LENS ON (B)(6) 2011 AND THE LENS WAS EXCHANGED FOR A SHORTER LENS ON (B)(6) 2011 DUE TO EXCESSIVE VAULT, ASSOCIATED WITH NARROWING OF THE ANGLE AND SHALLOWING OF THE ACD.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 ICL (IMPLANTABLE COLLAMER LENS) INTRAOCULAR LENS MTA STAAR SURGICAL CO. VICM 13.7 NA

Patients

Seq Age Sex Outcome Treatment
1 25 YR Required Intervention